Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women

---

Copy For Citation

BASBUG M., AYGEN E. M., TAYYAR M., Muhtaroglu S., Demir I., OKTEN S.

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.73, no.2, pp.149-152, 1997 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 73 Issue: 2
• Publication Date: 1997
• Doi Number: 10.1016/s0301-2115(97)02706-1
• Journal Name: EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.149-152
• Keywords: transdermal estradiol, conjugated estrogen, sex hormone-binding globulin, breast cancer, cardiovascular disease, ESTROGEN REPLACEMENT THERAPY, GROWTH-FACTOR-I, POSTMENOPAUSAL WOMEN, PLASMA, SERUM, 17-BETA-ESTRADIOL, PROGESTOGENS
• Erciyes University Affiliated: Yes

Abstract

Objective: To compare the effects of continuous noncombined transdermal estradiol versus oral conjugated estrogen on serum sex hormone-binding globulin (SHBG) levels prior to and during the 10th and 22nd weeks of therapy in patients with surgical menopause. Study design: Open, comparative trial. Patients were consecutively assigned to three groups: group 1 (n=18) received continuous transdermal estradiol (0.050 mg/day), group 2 (n=18) continuous oral conjugated estrogens (0.625 mg/day), whereas group 3 (n=15) received no treatment. Serum SHBG levels were determined before treatment and after 10 and 22 weeks of treatment. Results: Serum SHBG increased significantly with oral conjugated estrogens at 10 (p<0.01) and 22 weeks (p<0.01) compared with baseline. With transdermal estrogens there was a much smaller increase of SHBG. At 22 weeks, this increase was significant compared with baseline (p<0.05), but not compared with the control group (p>0.05). Conclusion: Transdermal estrogen has no effect on SHBG, whereas oral conjugated estrogens causes a considerable increase. (C) 1997 Elsevier Science Ireland Ltd.